Terms of Use

Welcome!

This Website (the “Site”), is owned by UCB, Inc. or its affiliates (“UCB”). We have drafted this Terms of Use Agreement (“Agreement”) to help you understand the rules that govern your use of the Site. If you do not agree to abide by all of the provisions contained in this Agreement, you may not use or access the Site.

The most current version of the Agreement can be reviewed by clicking on the “Terms of Use” hypertext link located at the bottom of the Site. UCB reserves the right to modify this Agreement at any time at its sole discretion. You should check the Site from time to time to review the then current Agreement because it is binding on you. Your continued use of the Site constitutes your acceptance of any changes to the Agreement.

This Agreement was last updated on August 22, 2019.

1. Scope

We control and operate this Site from the United States of America. If you are a non-US resident, you may access this Site solely at your own risk and are responsible for compliance with local laws and regulations, if applicable. Any references to products or services on the Site do not imply that UCB intends to announce or offer these products or services in your country.

2. Privacy

Your use of the Site will be governed by UCB’s Privacy Policy. By using the Site, you indicate that you understand and consent to the information collection, use, and disclosure practices described in our Privacy Policy.

3. Registered Users

UCB reserves the right to limit access to certain areas of the Site to certain users who register and meet the qualifications imposed by us. When registering, you must fill in all mandatory fields with true, accurate, current and complete information about yourself as prompted in the registration form and maintain and promptly update this information to keep it true, accurate, current and complete by contacting us. We reserve the right to discontinue access to any restricted area of the Site at any time, without notice to you, for any reason.

4. Security

If you are or become a registered user, you are responsible for maintaining the confidentiality of your User ID and password, and you are fully responsible for all activities that occur under your password or account. If you become aware of unauthorized use of your User ID and password, you agree to immediately notify UCB.

5. Modifications to Site

UCB reserves the right to modify or discontinue the Site (or any portion of the Site), temporarily or permanently, with or without notice to you, and is not obligated to support or update the Site. UCB shall not be liable to you or any third party in the event that UCB exercises its right to modify or discontinue the Site (or any portion of the Site). Unless explicitly stated otherwise, any new features that augment or enhance the current Site shall be subject to this Agreement.

6. No Medical Advice

The information on this Site is provided for general informational purposes only and is not intended or recommended as a substitute for professional medical advice. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment.

7. Intellectual Property Rights

The entire content included in the Site, including without limitation, the text, design, graphics, interface, sounds, music, video, interactive features and the like and the selection and arrangement thereof (“Content”) and the trademarks, service marks and logos contained therein (“Marks”), are owned by or licensed to UCB, its affiliates or subsidiaries, and are subject to copyright, trademark and other intellectual property rights under United States and foreign laws and international conventions.

All Content on the Site is provided to you AS IS for your information and personal use only.

You may download, view, copy and print Content, subject to the following conditions:

  • the Content may be used solely for personal, informational, or internal business purposes;
  • any and all copyright, trademark and other proprietary rights notices must appear on all copies, including the copyright notice at the bottom of the page;
  • the Content may not be modified or altered in any way; and
  • no graphics may be used separate from accompanying text.

Except as provided above, you may not use, download, upload, copy, print, display, perform, reproduce, publish, license, post, transmit, frame, mirror on another Web service, use any meta tags, inline any graphics or distribute any Content or information from the Site in whole or in part without the express permission of UCB. Requests for such permission should be made by contacting us. Any rights not expressly granted herein are reserved. Please be advised that UCB enforces its intellectual property rights to the fullest extent of the law.

8. User Submissions

To the extent that you add, upload, transmit, post, communicate, or store any content on the Site or otherwise submit any content for use by UCB (“User Submissions”), you are solely responsible for all of the information, statements, facts, and material contained in such User Submissions.

In connection with any User Submission you may submit, you agree not to transmit, distribute, post, communicate or store information or other material on, to, or through the Site that:

  • is copyrighted, unless you are the copyright owner;
  • infringes on any other intellectual property rights of others or on the privacy or publicity rights of others;
  • reveals a trade secret, unless you own it;
  • contains falsehoods or misrepresentations that could damage UCB (its successors and assigns) or any third party;
  • is obscene, libelous, defamatory, threatening, harassing, abusive, hateful, sexually-explicit, or embarrassing to any other person or entity as determined by UCB, in its sole discretion;
  • is illegal or otherwise objectionable;
  • constitutes advertisements or solicitations of business, surveys, contests, chain letters or pyramid schemes.

You understand that UCB does not guarantee that it will publish or maintain your User Submissions on the Site. UCB may remove User Submissions at any time, without prior notice and at its sole discretion. Moreover, UCB does not guarantee any confidentiality with respect to any User Submissions that you choose to add, upload, transmit, post, communicate or store on the Site or that UCB otherwise may receive from you.

UCB does not claim ownership of your User Submissions. However, by adding, uploading, transmitting, posting, communicating, or storing such User Submissions on the Site or by otherwise submitting such User Submissions to UCB, you agree to and hereby grant UCB, its successors and assigns, and the operators of the Site a worldwide, non-exclusive, royalty free, perpetual, irrevocable, transferable, and sub-licensable license to use, edit, modify, copy, reproduce, distribute, transmit, broadcast, display, create derivative works of, publish, perform, adapt, and display such User Submissions on or in connection with the Site and for such other purposes as UCB (its successors and assigns) may deem appropriate, in all media formats and in all media channels now known or later developed. You also hereby grant each user of the Site a non-exclusive license to access your User Submissions through the Site, and to use, reproduce, distribute, prepare derivative works of, display and perform such User Submissions.

9. Prohibited Uses Generally

You agree not to:

  • delete or revise any material or other information of any other user or UCB;
  • harvest or otherwise collect information about others, including e-mail addresses, without their consent;
  • take any action that imposes an unreasonable or disproportionately large load on the Site’s infrastructure;
  • use any device, software or routine to interfere or attempt to interfere with the proper working of the Site or any activity being conducted on the Site;
  • use or attempt to use any engine, software, tool, agent or other device or mechanism (including, without limitation, browsers, spiders, robots, avatars or intelligent agents) to navigate or search the Site other than the search engine and search agents available from UCB on the Site and other than generally available third-party Web browsers (e.g., Netscape Navigator and Microsoft Internet Explorer);
  • attempt to decipher, decompile, disassemble or reverse-engineer any of the software comprising or in any way making up a part of the Site;
  • solicit UCB members and guests to join outside sites or online services or organizations; or
  • disrupt the normal flow of dialogue, cause a screen to “scroll” faster than other users are able to type, or otherwise act in a manner that negatively affects other users’ abilities to engage in real time exchanges.

You further agree not to violate or attempt to violate the security of the Site, including, without limitation:

  1. accessing data not intended for you or logging into a server or account that you are not authorized to access;
  2. attempting to probe, scan or test the vulnerability of a system or network or to breach security or authentication measures without proper authorization; or
  3. attempting to interfere with service to any user, host, or network.

Violations of system or network security may result in civil or criminal liability. In accordance with this Agreement, UCB will investigate and work with law enforcement authorities to prosecute users who are involved in such violations.

10. Third-Party Content and Links to Third-Party Websites

The Site may provide links to other Websites operated by UCB as well as Websites operated by third parties. Please refer to the separate terms of use, privacy policies, and other rules posted on these linked sites before you use them. Third-party links are provided merely as a convenience to you, and the inclusion of any link does not imply affiliation or endorsement by UCB. UCB does not review, monitor or check the accuracy of content published on third-party sites, and is not responsible for the availability of, and content provided on, third-party sites. If you choose to purchase any products or services from a third party, your relationship is directly with the third party and UCB is not responsible for any loss or damage of any sort you may incur from dealing with any third party.

11. Notice of Copyright Infringement

If you believe that your work has been copied and is accessible on the Site in a way that constitutes copyright infringement, please provide UCB’s Copyright Agent with the following information:

  1. identification of the copyrighted work claimed to have been infringed;
  2. identification of the allegedly infringing material on the Site that is requested to be removed;
  3. your name, address, and daytime telephone number, and an e-mail address if available, so that UCB may contact you if necessary;
  4. a statement that you have a good faith belief that the use of the copyrighted work is not authorized by the copyright owner, its agent, or the law;
  5. a statement that the information in the notification is accurate and, under penalty of perjury, that the signatory is authorized to act on behalf of the owner of an exclusive copyright right that is allegedly infringed; and
  6. an electronic or physical signature of the copyright owner or someone authorized on the owner’s behalf to assert infringement of copyright and to submit the statement.

UCB’s Copyright Agent for notice of claims of copyright infringement on the Site can be reached by contacting us.

UCB will remove any content that infringes upon the copyright of any person under the laws of the United States upon receipt of such a statement (or, more specifically, any statement in conformance with 17 U.S.C. § 512(c)(3)). United States law provides significant penalties for submitting such a statement falsely. Please note that UCB may notify the individual who submitted the allegedly infringing material, and such person has the right to send UCB a counter-notification under applicable law and, if valid, the law requires the removed material to be restored. UCB will not be a party to disputes over alleged copyright infringement.

12. Disclaimer of Warranties

THE SITE AND ALL CONTENT, MATERIALS, INFORMATION, PRODUCTS AND SERVICES PROVIDED ON THE SITE, ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS. UCB EXPRESSLY DISCLAIMS ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, NON-INFRINGEMENT, AND SECURITY AND ACCURACY, AS WELL AS ALL WARRANTIES ARISING BY USAGE OF TRADE, COURSE OF DEALING, OR COURSE OF PERFORMANCE. UCB MAKES NO WARRANTY THAT: (A) THE SITE WILL MEET YOUR REQUIREMENTS; (B) THE SITE WILL BE AVAILABLE ON AN UNINTERRUPTED, TIMELY, SECURE, OR ERROR-FREE BASIS; (C) THE RESULTS THAT MAY BE OBTAINED FROM THE USE OF THE SITE OR ANY SERVICES OFFERED THROUGH THE SITE WILL BE ACCURATE OR RELIABLE; OR (D) THE QUALITY OF ANY PRODUCTS, SERVICES, INFORMATION, OR OTHER MATERIAL OBTAINED BY YOU THROUGH THE SITE WILL MEET YOUR EXPECTATIONS.

ANY CONTENT, MATERIALS, OR INFORMATION DOWNLOADED OR OTHERWISE OBTAINED THROUGH THE USE OF THE SITE IS DONE AT YOUR OWN DISCRETION AND RISK. UCB SHALL HAVE NO RESPONSIBILITY FOR ANY DAMAGE TO YOUR COMPUTER SYSTEM OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF ANY CONTENT, MATERIALS, OR INFORMATION.

NO ADVICE OR INFORMATION, WHETHER ORAL OR WRITTEN, OBTAINED BY YOU FROM UCB OR THROUGH THE SITE SHALL CREATE ANY WARRANTY NOT EXPRESSLY MADE HEREIN.

13. Limitation of Liability

IN NO EVENT SHALL UCB BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES, OR DAMAGES FOR LOSS OF PROFITS, REVENUE, DATA OR USE, INCURRED BY YOU OR ANY THIRD PARTY, WHETHER IN AN ACTION IN CONTRACT OR TORT, ARISING FROM YOUR ACCESS TO, OR USE OF, THE SITE OR ANY SERVICES PROVIDED THROUGH THE SITE, OR IN CONNECTION WITH ANY FAILURE OF PERFORMANCE, ERROR, OMISSION, INTERRUPTION, DEFECT, DELAY IN OPERATION OR TRANSMISSION, COMPUTER VIRUS, OR LINE OR SYSTEM FAILURE. IN THE EVENT THAT YOU HAVE A DISPUTE WITH ANOTHER USER RELATED TO, ARISING FROM, OR IN ANY WAY CONNECTED WITH USE OF THE SITE, YOU RELEASE UCB FROM ANY CLAIMS, DEMANDS, AND DAMAGES OF EVERY KIND AND NATURE ARISING OUT OF OR IN ANY WAY CONNECTED WITH SUCH A DISPUTE.

These limitations apply whether the alleged liability is based on contract, tort, negligence, strict liability, or any other basis, even if UCB has been advised of the possibility of such damage. Because some jurisdictions do not allow the exclusion or limitation of incidental or consequential damages, UCB’s liability in such jurisdictions shall be limited to the extent permitted by law.

14. No Resale of the Site

Your right to use the Site is personal to you. You agree not to reproduce, duplicate, copy, sell or resell the Site, without the express written consent of UCB.

15. Indemnity

You agree to indemnify, defend and hold UCB, its parents, subsidiaries, affiliates, shareholders, directors, officers, employees and agents, harmless from any claim, demand, liability, expense, or loss, including reasonable attorneys’ fees, made by any third party due to or arising out of, or in any way connected with your use of or access to the Site or your violation of this Agreement.

16. Export Restrictions/Legal Compliance

UCB controls this Site from within the United States of America. You may not access, download, use or export the Site or the Content in violation of US export laws or regulations, or in violation of any other applicable laws or regulations.

17. Choice of Law and Forum

These Terms shall be governed by and construed in accordance with the laws of the State of Georgia without regard to its choice of law provisions. If there is any dispute between us concerning the Agreement or your access to or use of the Site, we both agree to submit the dispute to non-binding mediation. The mediation will be governed under the rules of the American Arbitration Association, and the venue will be in Georgia.

18. Termination

UCB reserves the right, in its sole discretion, to terminate your access to and use of the Site, with or without notice. Otherwise applicable sections of the Agreement shall survive termination.

19. No Waiver

The failure of UCB to enforce any provisions of the Agreement or respond to a breach by you or other parties shall not in any way waive its right to enforce subsequently any terms or conditions of the Agreement or to act with respect to similar breaches.

20. Miscellaneous

You agree that no joint venture, partnership, employment, or agency relationship exists between you and UCB as a result of the Agreement or your access to and use of the Site. A printed version of the Agreement and of any notice given in electronic form shall be admissible in judicial or administrative proceedings based upon or relating to the Agreement to the same extent and subject to the same conditions as other business documents and records originally generated and maintained in printed form. Unless otherwise specified herein, the Agreement constitutes the entire agreement between you and UCB and governs your use of the Site. If any portion of the Agreement is held invalid or unenforceable, that portion shall be construed in a manner consistent with applicable law to reflect, as nearly as possible, the original intention of the parties, and the remaining portions shall remain in full force and effect.
UCB may assign its rights and duties under these Terms without such assignment being considered a change to the Terms and without notice to you. You may not assign these Terms without the prior written consent of UCB.

21. Contact Information

If you have any questions regarding this Agreement or the Site, please contact us.

INDICATION

NEUPRO is indicated for the treatment of Parkinson’s disease and moderate‐to‐severe primary Restless Legs Syndrome.
 

IMPORTANT SAFETY INFORMATION

NEUPRO contains sodium metabisulfite, a sulfite that may cause allergic‐type reactions including anaphylactic symptoms and life‐threatening or less severe asthmatic episodes in certain susceptible people and is seen more frequently in people with asthma. 

Patients treated with NEUPRO have reported somnolence and falling asleep without warning signs during activities of daily living, including driving, which sometimes resulted in accidents. Some patients believed they were alert immediately prior to the event. Patients may not recognize or acknowledge increased drowsiness or sleepiness. Therefore, prescribers should directly question patients about these possible occurrences and continually reassess patients, as some events have been reported well after the start of treatment. Patients should be advised to exercise caution while driving, operating heavy machinery, or working at heights during treatment with NEUPRO. If patients develop daytime sleepiness or episodes of falling asleep during activities of daily living, NEUPRO should be discontinued. 

There is an increased risk for hallucinations in patients with advanced‐stage Parkinson’s disease treated with NEUPRO. Patients with Parkinson’s disease or Restless Legs Syndrome may experience new or worsening mental status and behavioral changes, which may be severe, including psychotic behavior during NEUPRO treatment or after starting or increasing the dose of NEUPRO. 

NEUPRO may cause symptomatic postural/orthostatic hypotension, and Parkinson’s disease patients appear to have an impaired capacity to respond to a postural challenge. Both Parkinson’s disease and Restless Legs Syndrome patients treated with dopamine agonists require careful monitoring for signs and symptoms of postural hypotension, especially during dose escalation, and should be informed of this risk. NEUPRO may also cause syncope, elevated blood pressure, elevated heart rate, weight gain, and fluid retention. These events should be considered when treating patients with cardiovascular disease or concomitant illnesses.

Patients may experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge eating, and other intense urges, and the inability to control these urges while taking medications, including NEUPRO, that increase central dopaminergic tone. Dopamine dysregulation syndrome, the repeated use of more NEUPRO than as prescribed to manage symptoms, was observed in some patients during treatment with NEUPRO. Because patients may not recognize these behaviors as abnormal, prescribers should specifically ask patients and their caregivers about the development of new or increased urges while being treated with NEUPRO for Parkinson’s disease or Restless Legs Syndrome. Dose reduction or discontinuation of NEUPRO should be considered if such urges develop. 

NEUPRO may increase the dopaminergic side effects of levodopa and may cause or exacerbate pre-existing dyskinesia in patients with Parkinson’s disease. 

NEUPRO can cause application site reactions, and some may be severe. In clinical trials, most reactions were mild or moderate in intensity and were limited to the patch area.  

Use of dopaminergic medications, including NEUPRO, may cause augmentation and rebound in patients with Restless Legs Syndrome. 

NEUPRO should be removed before magnetic resonance imaging or cardioversion, because the aluminum backing layer in the patch could cause skin burns. Heat application has been shown to increase absorption several fold with other transdermal products. Therefore, patients should be advised to avoid exposing the application site to sources of direct heat, such as heating pads or electric blankets, heat lamps, saunas, hot tubs, heated water beds, and prolonged direct sunlight. 

Withdrawal symptoms such as apathy, anxiety, depression, fatigue, insomnia, sweating and pain may occur during taper or after discontinuation of NEUPRO. Patients who have been prescribed a lower dose or who have been withdrawn from the drug should be informed about potential withdrawal symptoms and monitored during and after discontinuation. 

The most common adverse reactions (at least 5% greater than placebo) for NEUPRO in the treatment of Parkinson’s disease are nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, disturbances in initiating and maintaining sleep, hyperhidrosis, visual disturbance, peripheral edema, and dyskinesia. The most common adverse reactions (at least 5% greater than placebo) for NEUPRO in the treatment of Restless Legs Syndrome are application site reactions, nausea, disturbances in initiating and maintaining sleep, somnolence, and headache.

Please see full Prescribing Information.